Beijing Balance Medical - Public Comps and Valuation Multiples

Beijing Balance Medical Overview

About Beijing Balance Medical

Beijing Balance Medical Technology Co Ltd is engaged in the research and development and production of animal-derived implantable medical devices. The company's products are used in heart valve replacement and repair, congenital heart disease implant intervention and surgical soft tissue repair.

Founded

2005

HQ

Employees

n/a

Website

bairenmedical.com

Sectors

Medical Devices
HealthTech
DeepTech

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$2.1B

Valuation Multiples

Multiples.vc

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Beijing Balance Medical Financials

Beijing Balance Medical has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Beijing Balance Medical achieved revenue of $51.1M and an EBITDA of $18.5M.

Beijing Balance Medical expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Beijing Balance Medical valuation multiples based on analyst estimates

Beijing Balance Medical P&L

	FY 2023	FY 2024	FY 2025	LTM	NTM
Revenue	$51.1M	n/a	XXX	XXX	XXX
Gross Profit	$30.6M	$36.3M	XXX	XXX	XXX
Gross Margin	60%	NaN%	XXX	XXX	XXX
EBITDA	$18.5M	n/a	XXX	XXX	XXX
EBITDA Margin	36%	NaN%	XXX	XXX	XXX
Net Profit	$7.1M	$13.1M	XXX	XXX	XXX
Net Margin	14%	NaN%	XXX	XXX	XXX
Net Debt	n/a	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

Beijing Balance Medical Stock Performance

As of April 15, 2025, Beijing Balance Medical's stock price is CNY 110 (or $15).

Beijing Balance Medical has current market cap of CNY 15.2B (or $2.1B), and EV of CNY 14.9B (or $2.1B).

See Beijing Balance Medical trading valuation data

Beijing Balance Medical Stock Data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$2.1B	$2.1B	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Beijing Balance Medical Valuation Multiples

As of April 15, 2025, Beijing Balance Medical has market cap of $2.1B and EV of $2.1B.

Beijing Balance Medical's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Beijing Balance Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See valuation multiples for Beijing Balance Medical and 10K+ public comps

Beijing Balance Medical Financial Valuation Multiples

	FY 2024	FY 2025E	FY 2026E	FY 2027E
EV	$2.1B	XXX	XXX	XXX
EV/Revenue	n/a	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	XXX	XXX
P/E	n/a	XXX	XXX	XXX
P/E/Growth	n/a	XXX	XXX	XXX
EV/FCF	n/a	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Beijing Balance Medical Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Beijing Balance Medical Valuation Multiples

Beijing Balance Medical's NTM/LTM revenue growth is n/a

Beijing Balance Medical's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.

Over next 12 months, Beijing Balance Medical's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .

Analysts estimate Beijing Balance Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See operational valuation multiples for Beijing Balance Medical and other 10K+ public comps

Beijing Balance Medical Operational Valuation Multiples

	FY 2024	NTM	FY 2025E	FY 2026E	FY 2027E
Revenue Growth	n/a	XXX	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	XXX	XXX	XXX
Rule of 40 (SaaS-only)	n/a	XXX	XXX	XXX	XXX
Revenue per Employee	n/a	XXX	XXX	XXX	XXX
Opex per Employee	n/a	XXX	XXX	XXX	XXX
S&M Expenses to Revenue	17%	XXX	XXX	XXX	XXX
G&A Expenses to Revenue	3%	XXX	XXX	XXX	XXX
R&D Expenses to Revenue	27%	XXX	XXX	XXX	XXX
Opex to Revenue	62%	XXX	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry